The US Food and Drug Administration has expanded its indications for the Evolut family of valves (Medtronic) to include redo TAVI inpatients at high risk for surgery. The approval now includes use for ...
During valve-in-valve TAVI procedures using the Sapien 3 balloon-expandable valve (Edwards Lifesciences) as the second prosthesis, downsizing and underexpansion are frequently observed, particularly ...
The latest generation of Medtronic’s transcatheter aortic valve replacement implant has passed the FDA’s muster. Like those that came before it, the new Evolut FX+ is placed through a minimally ...
Patients with severe aortic stenosis at low surgical risk who underwent supra-annular, self-expanding Evolut transcatheter aortic valve replacement (TAVR) had similar rates of death or disabling ...
A minimalist strategy of local anesthesia without sedation may be as safe and feasible as a standard-of-care approach that includes conscious sedation for many patients undergoing transcatheter aortic ...
Medtronic’s newest generation Evolut FX transcatheter aortic valve replacement system (TAVR) significantly improved commissure alignment during TAVR procedures compared to earlier generations, ...
Medtronic is launching its fourth generation transcatheter aortic valve implantation (TAVI) system, the Evolut FX, in Europe this week, after announcing CE mark for the system last week. FDA approved ...
A minimalist approach to transcatheter aortic valve implantation (TAVI), without sedation, was noninferior to the standard approach for the primary outcome at 30 days, according to late-breaking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results